NCT00003390View on ClinicalTrials.gov

6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 1998

Study Completion Date

August 31, 2004

Conditions
Kidney Cancer
Interventions
DRUG

irofulven

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00003390 - 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter